Skip to main content
Premium Trial:

Request an Annual Quote

Athersys Wins Diabetes Grant from JDRF

This article has been corrected. A previous version erroneously stated that the JDRF program had $600 million. The JDRF said it does not release the dollar figure on research funding available under its program. GenomeWeb regrets the error.


NEW YORK, June 4 (GenomeWeb News) - Cleveland, Ohio-based Athersys announced today that it has received a grant from the Juvenile Diabetes Research Foundation to use its protein expression and stem cell technology to look for proteins that promote the formation of pancreatic islet cells.


The grant was provided as part of JDRF's Industry Discovery and Development Partnership Program. William Lehman, executive vice president, corporate development and finance of Athersys, said that the value of the grant was "in the six figures."


Athersys will use its RAGE protein expression technology with its MAPC adult stem cell technology to identify, isolate, and characterize proteins that cause the differentiation of stem cells into pancreatic islet cells.


Athersys has developed RAGE and GECKO - which stands for genome-wide cell-based knockout technology - for use in drug target validation and therapeutic development applications.


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.